Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP000573)
SBP Name
beta-Hairpin mimetic Murepavadin
Synonyms
POL7080; POL 7080 acetate; RG 7929; RO 7033877
Molecular Weight 1.6 kDa
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase III
Sequence Length 14
SBP Sequence
>beta-Hairpin mimetic Murepavadin
AS[d-Pro]PTWI[Dab][Orn][d-Dab][Dab]W[Dab][Dab]
Sequence Description The first Ala and the last Dab form a bridge.
Protein Scaffold Information of This SBP
Scaffold ID PS016
Scaffold Info
[1] , [2] , [3]
Scaffold Name Beta-Hairpin mimetic
Scaffold Class Non-Antibody
Fold Type Beta-Sheets + Beta-Turn
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
C-X-C chemokine receptor type 4
BTS Info
Inhibitor Bacterial pneumonia [ICD-11: CA40.0Z]; Pseudomonas aeruginosa [ICD-11: XN5L6] N.A. Polyphor [1] , [2] , [3]
Clinical Trial Information of This SBP
NCT02096315 Click to show the Detail
Indication Acute Exacerbation of Non-cystic Fibrosis Bronchiectasis Due to Pseudomonas Aeruginosa Infection
Phase Phase II
Title A Phase II, Open-label, Multicenter Study to Assess the Tolerance, Safety, Efficacy and Pharmacokinetics/Pharmacodynamics (PK/PD) of POL7080 in the Treatment of Patients With Acute Exacerbation of Non-cystic Fibrosis Bronchiectasis Due to Pseudomonas Aeruginosa Infection Requiring Intravenous Treatment
Status Terminated
Sponsor Polyphor Ltd
NCT02096328 Click to show the Detail
Indication entilator- Associated Pneumonia (VAP) Due to Suspected or Documented Pseudomonas Aeruginosa Infection
Phase Phase II
Title A Phase II, Open-label, Multi-center Study to Assess Pharmacokinetics (PK), Safety and Efficacy of POL7080 Co-administered With Standard of Care (SoC) Treatment in Patients With Ventilator-Associated Pneumonia (VAP) Due to Suspected or Documented Pseudomonas Aeruginosa Infection
Status Completed
Sponsor Polyphor Ltd
NCT02110459 Click to show the Detail
Indication Renal Impairment
Phase Phase I
Title An Open-label, Non-randomized, Monocenter, Single-dose, Phase I Study to Evaluate Pharmacokinetics and Safety of POL7080 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
Status Completed
Sponsor Polyphor Ltd
NCT02897869 Click to show the Detail
Indication Healthy
Phase Phase I
Title A Single-center, Open-label, Two Sequence, Crossover Study to Investigate the Interaction Between Amikacin and POL7080 in Healthy Subjects
Status Completed
Sponsor Polyphor Ltd
NCT03409679 Click to show the Detail
Indication Pneumonia
Phase Phase III
Title A Multicenter, Open-label, Randomized, Active-controlled, Parallel Group, Pivotal Study to Investigate the Efficacy, Safety and Tolerability, and Pharmacokinetics of?Murepavadin?Combined With One Anti-pseudomonal Antibiotic Versus Two Anti-pseudomonal Antibiotics in Adult Subjects With Ventilator-associated Bacterial Pneumonia Suspected or Confirmed to be Due to Pseudomonas Aeruginosa
Status Terminated?(Safety Data Review)
Sponsor Polyphor Ltd
NCT03582007 Click to show the Detail
Indication Pneumonia
Phase Phase III
Title A Multicenter, Open Label, Sponsor Blinded, Randomized, Active Controlled, Parallel Group, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability of?Murepavadin?Given With Ertapenem Versus an Anti-pseudomonal-beta-lactam-based Antibiotic in Adult Subjects With Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas Aeruginosa
Status Terminated?(Safety Data Review)
Sponsor Polyphor Ltd
References
1 Polyphor. Product Development Pipeline. 2021.
2 Protein Epitope Mimetics: From New Antibiotics to Supramolecular Synthetic Vaccines. Acc Chem Res. 2017 Jun 20;50(6):1323-1331.
3 DRUGBANK online. Murepavadin